Camostat With Bicalutamide for COVID-19

Summary

This will be a randomized, open-label study to determine if camostat+ bicalutamide decreases the proportion of people with COVID-19 who require hospitalization, compared to historical controls. Patients with symptomatic COVID-19, diagnosed as outpatients, will be randomized 1:1, stratified by gender, to treatment with standard of care alone (Arm 1) or with camostat and bicalutamide (Arm 2).

Timeline

Start

2021-02-03

Primary completion

2021-09-15

Completion

2021-09-15

Drugs

Indications